---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-078839"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2026-06-29T20:16:08+00:00"
generated_at: "2026-06-29T20:17:51.938204+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Acura extends loan maturity and NDA deadline with AD Pharma, warns of possible shutdown

## Summary
- Received $200,000 loan from AD Pharma on June 24, 2026, bringing principal balance to $10,694,279 with accrued interest of ~$1.16M.
- Extended NDA acceptance deadline for LTX-03 from June 30, 2026 to December 31, 2026 via amendment #14 to license agreement.
- Extended maturity date of secured promissory note from June 30, 2026 to December 31, 2026 via amendment #8.
- Extended warrant expiration date to December 31, 2026 and noted AD Pharma owns ~65% of outstanding common stock.
- Warns that without additional financing by late July 2026, may need to scale back operations, furlough employees, or seek bankruptcy protection.

## SEC filing metadata
- accession: 0001104659-26-078839
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2026-06-29T20:16:08+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465926078839/0001104659-26-078839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465926078839/tm2619325d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-078839
- JSON: https://secwatch.observer/filing/0001104659-26-078839.json
- Plain text: https://secwatch.observer/filing/0001104659-26-078839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.